Huida claims first CRISPR injected into a human brain; YolTech's LNP edit becomes China's first in-vivo gene-editing drug in trials
In Vivo Editing
Phase 3 HAELO cut hereditary-angioedema attacks 87%; rolling BLA for lonvo-z opens the path to the first marketed in-body gene edit